T863

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

T-863（DGAT-1抑制剂）是一种口服活性、选择性和有效的DGAT1（酰基辅酶A：二酰基甘油酰基转移酶1）抑制剂，与DGAT1的酰基辅酶A结合位点相互作用，并抑制细胞中三酰基甘油的合成。

T-863(DGAT-1 inhibitor) is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells. IC50 value: Target: DGAT1 T863 causes weight loss, reduction in serum and liver triglycerides, and improved insulin sensitivity in obese mice.

——

Animal Model:C57BL6 normal mice (8 weeks old) or diet-induced obese (DIO) mice (10 months old, fed a high fat diet for 8 months).Dosage:30 mg/kg (5 μL/g)Administration:Oral administration; once a day for days 1-7 and twice a day for days 8-14 Result:Significantly delayed fat absorption and resulted in lipid accumulation in the distal small intestine of mice, mimicking the effects of genetic ablation of DGAT1.

T863, T 863, T-863

Cell Cycle/DNA Damage

DNA/RNA Synthesis

DGAT1

Metabolic Disease

——

701232-20-4

394.47

C22H26N4O3

>98% (HPLC)

DMSO : ≥ 50 mg/mL; 126.75 mM

O=C(O)C[C@@H]1CC[C@H](CC1)c2ccc(cc2)C4=Nc3c(ncnc3N)OC4(C)C

trans-4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexaneacetic acid

(-20℃)

With Ice Pack

≥ 2 years